Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cilazapril monohydrate
Drug ID BADD_D00465
Description Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.
Indications and Usage Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.
Marketing Status approved
ATC Code C09AA08
DrugBank ID DB01340
KEGG ID D07699; D01069
MeSH ID D017315
PubChem ID 56329
TTD Drug ID D04GKO
NDC Product Code Not Available
UNII 19KW7PI29F
Synonyms Cilazapril | Cilazapril Monohydrobromide | Cilazapril, Anhydrous | Cilazapril Anhydrous | Cilazapril Monohydrate | Ro 31-2848 | Ro 31 2848 | Ro 312848 | Ro-31-2848 | Ro312848 | Cilazapril Hydrate | Cilazapril, (S*)-Isomer | Inhibace
Chemical Information
Molecular Formula C22H33N3O6
CAS Registry Number 92077-78-6
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC2CCCN3CCCC(N3C2=O)C(=O)O.O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Polyuria20.02.03.002--Not Available
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.004--
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Renal artery stenosis24.04.11.001; 20.01.07.005--Not Available
Renal failure20.01.03.005--Not Available
Renal pain20.02.03.003--Not Available
Rhinitis11.01.13.004; 22.07.03.006--
Scleroderma15.06.01.002; 23.03.02.005; 10.04.07.001--Not Available
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Urethral disorder20.07.01.002--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages